PRMT6 and neoplasm: Interestingly, in glioblastoma (a cancer cell type that contains stem cells involved in therapy resistance) a molecule (EPZ020411) that inhibits PRMT6-mediated arginine methylation of the RCC1 protein prevents its stabilization, thereby improving the cytotoxic activity of radiotherapy in these tumours [131].